SC
DMRA

Steven Cohen’s Damora Therapeutics DMRA Stock Holding History

Steven Cohen’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Sell
48,754
-1,144,954
-96% -$27.7M ﹤0.01% 2680
2026
Q1 		$30.9M Buy
1,193,708
+1,084,708
+995% +$27.9M 0.04% 593
2025
Q4 		$2.51M Buy
+109,000
New +$1.89M ﹤0.01% 2336

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Steven Cohen's DMRA Position: Q2 2026 in Review

Steven Cohen reduced its Damora Therapeutics (DMRA) stake by 96% in Q2 2026, selling an estimated $27.7M and leaving 48,754 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2680.

Steven Cohen first reported a position in DMRA in Q4 2025 and has held it in 3 quarters since. The position peaked at $30.9M in Q1 2026. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Steven Cohen held 48,754 shares of Damora Therapeutics worth $1.27M as of Q2 2026.
  • Steven Cohen sold 1,144,954 Damora Therapeutics shares in Q2 2026, an estimated $27.7M.
  • Damora Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2680 holding.
  • Steven Cohen first reported a position in Damora Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Steven Cohen's Damora Therapeutics position peaked at $30.9M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.